<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323687</url>
  </required_header>
  <id_info>
    <org_study_id>GS-DE-164-0106</org_study_id>
    <nct_id>NCT00323687</nct_id>
  </id_info>
  <brief_title>SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada</brief_title>
  <official_title>Switch to a Completely ONce Daily Regimen Containing Emtricitabine/Tenofovir - Fixed Dose Combination Plus Third QD Partner: &quot;SONETT&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an unmet medical need for potent ART regimens that make adherence to treatment even
      easier due to QD dosing, offer a good tolerability profile and fit into the daily life of
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HIV RNA &lt; 400 and with HIV RNA &lt; 50 copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HIV RNA &lt; 400 and with HIV RNA &lt; 50 copies/mL at Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure or ART discontinuation. Virological failure is defined as 2 consecutive measurements 4 weeks apart with viral load of HIV-RNA &gt; 400 copies/mL</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV-1 Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients (over 18 years of age) of any ethnic group without restricted legal
        competence and who are capable of following the study instructions HIV-1 infection
        documented by confirmed positive HIV-1 antibody test and/or positive PCR for HIV-1 RNA
        Stable (no interruption or change of regimen in last 3 months) AZT-and 3TC-containing
        regimen &gt; 3 months No documented prior virologic failure (virological failure defined as 2
        consecutive measurements 4 weeks apart with viral load of HIV-RNA &gt; 400 copies/mL while on
        ART) CD4+ counts &gt; 50 cells/µL Viral load &lt; 50 copies/mL Karnofsky performance status ≥ 80%
        For women with childbearing potential, negative urine pregnancy test at Screening visit

        Exclusion Criteria:

        Serum phosphate level &lt; 0.65 mmol/L Documented active opportunistic infections Subjects
        with previously documented K65R, 69S mutations or 3 or more thymidine analogue mutations
        Documented active malignant disease (excluding Kaposi sarcoma limited to the skin) Female
        of childbearing potential not willing to use a barrier method of contraception during
        heterosexual intercourse during the duration of study Women who are pregnant or breast
        feeding Known history of drug, medication or alcohol abuse within the last 12 months
        preceding the study Simultaneous participation in another study with an investigational
        drug or within less than one month prior to this study Inability or not willing to meet the
        requirements of the protocol History of seizures, central nervous system disorders or
        psychiatric disability thought to be clinically significant in the opinion of the
        investigator Limited mental capacity to the extent that he/she cannot provide informed
        consent or information regarding adverse events of the study medication Renal disease
        (creatinine clearance &lt; 50 ml/min according to Cockroft_Gault formula) or severe hepatic,
        respiratory or cardiovascular disease Patients who have previously been enrolled into this
        study Contraindication for one of the study substances.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Mertenskoetter</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gilead Sciences GmbH</name>
      <address>
        <city>Martinsried</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <last_update_submitted>June 6, 2008</last_update_submitted>
  <last_update_submitted_qc>June 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thomas Mertenskoetter</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>HIV-1 Infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

